Company news
Kezar Life Sciences, Inc. (NASDAQ:KZR) news
Kezar Life Sciences, Inc. news releases on 6ix. Latest, Jun 8, 2021: Kezar Life Sciences Announces Formation of Clinical Advisory Committee
Press releases — page 2
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
June 7, 2021
Kezar Presents Results of the Completed MISSION Phase 1b Study of KZR-616 at EULAR 2021
June 1, 2021
Kezar Appoints Rheumatology Industry Expert, Micki Klearman, MD, to its Board of Directors
May 31, 2021
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates
May 11, 2021
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting
April 9, 2021
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates
March 10, 2021
Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
November 11, 2020
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates
November 4, 2020
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
October 22, 2020
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
August 4, 2020
Kezar Announces Proposed Public Offering of Common Stock
June 7, 2020
Kezar Announces Pricing of a Public Offering of $46.7 million of Common Stock and Pre-Funded Warrants
June 7, 2020
Kezar Provides Data Update from MISSION Study of KZR-616
June 2, 2020
Kezar Announces Presentations During Upcoming Scientific Conferences
May 19, 2020
Kezar Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
May 6, 2020
Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer
May 3, 2020
Kezar Provides Statement Regarding COVID-19 Pandemic
April 8, 2020
Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
March 11, 2020
Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants
February 3, 2020
Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants
January 30, 2020
Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 29, 2020
Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors
December 18, 2019
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
November 11, 2019
Kezar Life Sciences to Host Conference Call and Webcast during the American College of Rheumatology Annual Meeting to Discuss Updated Results with KZR-616
November 7, 2019
Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
November 5, 2019
Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
September 30, 2019